Loading...
XNAS
NPCE
Market cap546mUSD
Dec 05, Last price  
16.40USD
1D
-3.36%
1Q
68.55%
IPO
-35.53%
Name

Neuropace Inc

Chart & Performance

D1W1MN
XNAS:NPCE chart
P/E
P/S
6.84
EPS
Div Yield, %
Shrs. gr., 5y
4.10%
Rev. gr., 5y
16.67%
Revenues
80m
+22.14%
36,972,00041,138,00045,183,00045,520,00065,421,00079,906,000
Net income
-27m
L-17.64%
-40,740,000-35,982,000-38,109,000-53,370,000-32,956,000-27,141,000
CFO
-18m
L-8.89%
-25,026,000-21,609,000-24,577,000-36,869,000-19,701,000-17,949,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
IPO date
Apr 22, 2021
Employees
169
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT